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Jennifer L. Moran, Steven A. McCarroll, Michael C. O’Donovan, and Michael J. OwenBackground: Several recurrent copy number variants (CNVs) have been shown to increase the risk of developing schizophrenia (SCZ),
developmental delay (DD), autism spectrum disorders (ASD), and various congenital malformations (CM). Their penetrance for SCZ has
been estimated to be modest. However, comparisons between their penetrance for SCZ or DD/ASD/CM, or estimates of the total
penetrance for any of these disorders have not yet been made.
Methods: We use data from the largest available studies on SCZ and DD/ASD/CM, including a new sample of 6882 cases and 6316
controls, to estimate the frequencies of 70 implicated CNVs in carriers with these disorders, healthy control subjects, and the general
population. On the basis of these frequencies, we estimate their penetrance. We also estimate the strength of the selection pressure
against CNVs and correlate this against their overall penetrance.
Results: The rates of nearly all CNVs are higher in DD/ASD/CM compared with SCZ. The penetrance of CNVs is at least several times
higher for the development of a disorder from the group of DD/ASD/CM. The overall penetrance of SCZ-associated CNVs for developing
any disorder is high, ranging between 10.6% and 100%.
Conclusions: CNVs associated with SCZ have high pathogenicity. The majority of the increased risk conferred by CNVs is toward the
development of an earlier-onset disorder, such as DD/ASD/CM, rather than SCZ. The penetrance of CNVs correlates strongly with their
selection coefﬁcients. The improved estimates of penetrance will provide crucial information for genetic counselling.Key Words: Autism spectrum disorder, developmental delay,
CNV, penetrance, schizophrenia, selection
Anumber of rare genomic rearrangements, called copy numbervariants (CNVs) have been shown to increase the risk ofdeveloping early-onset neurodevelopmental disorders. These
were ﬁrst identiﬁed in patients with characteristic and recognizable
syndromic features (e.g., Williams-Beuren syndrome, Smith-Magenis
syndrome, Sotos syndrome, DiGeorge/velo-cardio-facial syndrome
[VCFS]). Over the past few years with the introduction of high-
throughput microarray technologies, more CNVs of smaller size and
incomplete penetrance have also been identiﬁed. Some of these
have been shown to also increase the risk of developing SCZ, ASD,
and other neuropsychiatric disorders. For example, in 2008–2009, a
deletion at 15q13.3 was shown to increase the risk of developing
developmental delay (DD) (1), schizophrenia (SCZ) (2,3), epilepsy (4),
and autism (5). Similar ﬁndings of increased risk for developing SCZ,
DD, and autism spectrum disorders (ASD) were made for deletions
at 1q21.1 and 15q11.2 and duplications at 16p11.2 and 16p13.11
(reviewed by Malhotra and Sebat) (6). A number of CNVs have now
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tions (CM) (6–9).
The number of CNVs known to increase the risk of developing
a disorder from the group of DD/ASD/CM is higher than those
implicated in SCZ. Thus, Girirajan et al. (7) tested 32,587 samples
from children who had DD or ASD with or without CM for 72 CNV
regions (39 deletions and 33 reciprocal duplications) that had
previously been implicated in neurodevelopmental phenotypes or
genomic disorders, including nine of uncertain pathogenic sig-
niﬁcance. When compared with a set of 8329 healthy control
subjects, 38 (25 deletions and 13 duplications) were nominally
statistically associated with the disorders (at p  .05), and several
more showed trends that might also represent true associations if
tested in larger samples. Similar results were reported by Kaminsky
et al. (8) on 15,749 individuals who presented for diagnostic array
testing with abnormal clinical phenotypes including DD, intellec-
tual deﬁcit, ASD, and/or multiple CM. These authors reported that
21 CNV regions (14 deletions and 7 duplications) were signiﬁcantly
associated with one or more of these disorders.
It is clinically important to know the risk to carriers of these
CNVs for developing each of the possible associated disorders (i.
e., their penetrance). Vassos et al. (9) were the ﬁrst to estimate the
penetrance for SCZ for seven CNVs that had been shown to
increase risk for this disorder. They found rather modest rates of
2% to 7.4% except for the VCFS deletion on 22q11.2, which had a
much higher penetrance of 55%, although with broad conﬁdence
intervals because no CNV was observed in control subjects. The
authors concluded that these CNVs were neither necessary nor
sufﬁcient to cause the disorder and that the level of penetrance
was not sufﬁcient for them to be considered as useful clinical
tools in genetic counselling, diagnosis, and testing. However, they
pointed out that the overall penetrance for any neuropsychiatric
disorder was likely to be much higher. The penetrance of 12 CNVs
for DD/ASD/CM was estimated by Rosenfeld et al. (10). EstimatesBIOL PSYCHIATRY 2014;75:378–385
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15q11.2 deletions to 62.4% for distal 16p11.2 deletions. These
values are much higher than those for SCZ. The most highly
penetrant CNVs were not tested because their absence in control
subjects prevented accurate estimates.
Here we estimate the penetrance of all CNVs listed in
the Girirajan et al. (7) article. Nearly all SCZ-associated CNVs
are on this list as well, and we added only exonic deletions at
NRXN1, a gene consistently implicated in SCZ (11–13). We
performed estimates for both SCZ and the group of early-
onset developmental disorders: DD/ASD/CM. This joint analysis
allowed us to provide estimates for each CNV, even for those
that are never found in SCZ or in healthy control subjects. We
use a large new sample of cases and controls and add to this
the data from the two largest previous studies on SCZ or from
previous meta-analyzes to derive more reliable estimates.Methods and Materials
Choice of CNVs
We analyzed CNVs previously associated with SCZ or severe
neurodevelopmental phenotypes. These were taken from the list
of CNV regions proposed by Girirajan et al. (7): 37 deletions and 32
reciprocal duplications, after excluding an overlapping segment at
17p13.3 and a CNV on the X chromosome because the
X chromosome was not analyzed in our samples. Most of the
strongly implicated SCZ-associated CNVs are on this list, but we
added exonic deletions at NRXN1. For some of the analyzes, we
focus on CNVs that we regard as associated with SCZ (Table 1),
based on the review by Malhotra and Sebat (6), with the addition
of NRXN1 and newly implicated loci (Table S2 in Supplement 1).
We did not analyze other SCZ-implicated loci (e.g., VIPR2 duplica-
tions) because they have not been tested in sufﬁciently large
samples of DD/ASD/CM or have not received consistent support.
Estimating the Rate of CNVs in Different Disorders
We only included data from the largest studies/samples
available to simplify the presentation. The numbers that follow
are those after exclusion of poorly performing arrays and
duplicate samples. A CNV was called as covering a CNV locus if




Locus Controls SCZ DD/ASD/CM
1q21.1 del .26 .021 .17 .29
1q21.1 dup .23 .038 .13 .2
NRXN1 del .23 .02 .18 .18
3q29 del .83 .0014 .082 .061
WBS dup .61 .0058 .066 .12
15q11.2 del .09 .28 .59 .81
Prader-Willi/Angelman dup .5 .0083 .079 .25
15q13.3 del .31 .019 .14 .26
16p13.11 dup .13 .13 .31 .3
16p11.2 distal del .29 .018 .063 .14
16p11.2 dup .33 .03 .35 .28
17q12 del .68 .0054 .036 .087
DiGeorge/VCFS del .8 0 .29 .54
The full list of CNVs is presented in Table S4 of Supplement 1.
ASD, autism spectrum disorders; CI, conﬁdence interval; DD, developmental
VCFS, velo-cardio-facial syndrome; WBS, Williams-Beuren syndrome.(Table S2 in Supplement 1). In the case of loci that include only
single genes (NRXN1, SIM1, YWHAE, PAFAH1B1, and NF1), we
accepted CNVs that intersected at least one exon of the gene.
The rates of CNVs in DD/ASD/CM are taken from the largest
study on these phenotypes: 32,587 patients referred for genetic
testing to one laboratory (Signature Genomics) described by
Girirajan et al. (7). For some of the loci, the reported sample
numbers are smaller (23,380), for others they are larger (33,226)
because the same team subsequently published data on several
CNVs in an enlarged data set (10).
For SCZ cases, we analyzed three large data sets where we had
access to the raw data, for a total of at least 13,465 cases (and more
for the SCZ-associated loci, see below): 1) 6882 patients from our
new Clozapine UK and Cardiff University Cognition in Schizophrenia
samples (Supplement 1), 2) 3391 cases from the International
Schizophrenia Consortium study (ISC, 2008) (2), and 3) 3192 cases
from the Molecular Genetics of Schizophrenia (MGS) study (dbGAP
accession numbers phs000167.v1.p1 and phs000021.v3.p2).
For controls, we analyzed samples from four publicly available
data sets genotyped with high-resolution Illumina arrays (San
Diego, California), similar to our new SCZ sample and analyzed by
us with the same methods. These include individuals who took
part in a study on smoking cessation in the United States (n ¼
1488); a study on melanoma in the United States (n ¼ 2971); a
study on refractive error Kooperative Gesundheitsforschung in
der Region Augsburg (KORA) study from Germany (n ¼ 1857),
and the Wellcome Trust Case Control Consortium (WTCCC2) in
the United Kingdom (n ¼ 4939). To those we added 3181 control
subjects from the ISC and 3437 control subjects from the MGS
studies listed above, for a total of 17,873 control subjects.
For the SCZ-associated loci, we added data from previous
studies, as reviewed by Malhotra and Sebat (6) or presented in the
relevant articles that implicated them (Table S2 in Supplement 1).
For these loci we excluded our WTCCC2 control subjects because
they are completely or partially included in the previous reviews.
Estimation of the penetrance was performed with an adaptation
of the method proposed by Vassos et al. (9). These authors estimated
the penetrance as the probability of developing the disease (D) for
individuals carrying the CNV (G) with the following formula:
PðDjGÞ ¼ PðGjDÞPðDÞ
PðGjDÞPðDÞPðGjDÞPðDÞCopy Number Variants Only
% Penetrance % (95% CI)
General Population SCZ DD/CM/ASD Total
.033 5.2 (2.5–11) 35 (18–67) 40 (20–78)
.045 2.9 (1.3–6.3) 18 (10–33) 21 (11–39)
.028 6.4 (2.5–8.3) 26 (16–80) 33 (18–88)
.0046 18 (4.7–67) 53 (15–100) 71 (20–100)
.011 6.0 (1.4–20) 44 (13–100) 50 (14–100)
.3 2.0 (1.4–2.7) 11 (8.2–14) 13 (9.6–17)
.019 4.2 (1.4–12) 54 (25–100) 58 (26–100)
.03 4.7 (2.2–9.9) 35 (19–62) 40 (21–72)
.14 2.2 (1.3–3.7) 8.4 (5.7–13) 10.6 (7–17)
.024 2.6 (.8–9.2) 23 (8.4–63) 26 (9.2–72)
.043 8.0 (4.3–14) 26 (18–43) 34 (22–57)
.009 4.0 (.8–18) 39 (13–100) 43 (14–100)
.024 12 (6.5–18) 88 (53–100) 100 (60–100)
delay; del, deletion; dup, duplicate; CM, various congenital malformations;
www.sobp.org/journal
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the lifetime morbid risk for SCZ. Instead of using one single disease
population and controls, we substitute the denominator with the
estimate of the CNV frequency in the general population (P(CNV
general)), which includes patients with SCZ and the group of DD/
ASD/CM. The frequency in the general population is therefore likely
to be higher than the rate among control subjects.
Estimating the Frequency of the CNV in the General
Population
This method was described in our previous publication (14).
Brieﬂy, we must take into account that if a CNV has a high
penetrance for disorders that are underrepresented among
populations recruited as healthy control subjects (e.g., DD/SCZ/
CM), then the measured frequency of that CNV among healthy
control subjects would be an underestimate of the population
frequency. To minimize this effect, we took into account the rate
of these CNVs in all disorders that are likely to be excluded from
“control” populations. The overall frequency of a CNV in the
general population P(CNV general) is therefore:
P CNV generalð Þ ¼ P CNVjconð ÞP conð ÞP CNV jSCZð ÞP SCZð Þ
P CNVjDD=ASD=CM P DD=ASD=CM 
that is, the sum of the products of the conditional probabilities of
being a carrier of the CNV given the phenotype, and the
proportion of people with this phenotype in the population).
We accepted a frequency of SCZ in the population of 1%. The
frequency of DD/ASD/CM was approximated at 4%. The 4% ﬁgure
is a compromise based on the ﬁgure of 5.12% for the total
frequency of diseases with an important genetic component,
proposed by Baird et al. (15). This latter ﬁgure was used by
Rosenfeld et al. (10) for calculating the penetrance of CNVs.
However, it includes some individuals with psychosis and some
with disorders that are unlikely to be referred for genetic testing,
as in the population investigated by Girirajan et al. (7). A lower
end of the frequency of these disorders could be the sum of the
widely accepted rates of 2% for DD (16) and 1% for ASD (17,18),
that is, 3%, the number that we used in our previous publication
(14). Therefore, we accepted 4% as a reasonable compromise that
also includes some congenital malformations. As shown later in
the article, even large errors in these estimates make little
difference to our conclusions because the combined rate of
DD/ASD/CM in the population is still several times higher than
that of SCZ under any assumptions.
Therefore, the frequency of a CNV in the general population can
be expressed as the sum of the frequencies among healthy control
subjects (comprising 95% of the general population that excludes
the disorders)  the frequency among SCZ (comprising 1% of the
general population)  the frequency among the DD/ASD/CM
patients (comprising the remaining 4% of the general population):
P(CNV general) ¼ P(CNV|con).95  P(CNV|SCZ).01
 P(CNV|DD/ASD/CM).04
The penetrance for SCZ (in the range of 0–1) then simpliﬁes to
PðSCZjGÞ ¼ PðCNV jSCZÞ  :01
PðCNV generalÞ
The penetrance for DD/ASD/CM simpliﬁes to
PðDDjASDjCMjGÞ ¼ PðCNVjDD=ASD=CMÞ  :04
PðCNV generalÞwww.sobp.org/journalThe total penetrance for any of these disorders is simply the sum
of those for SCZ and DD/ASD/CM.
To illustrate the method, we provide an example of the
penetrance of the 1q21.1 deletion. It is found in .021% of
reported control subjects, in .17% of SCZ patients, and .24% of
patients affected with DD/ASD/CM (Table 1). This results in a
frequency in the general population of .033%: (.00021  .95) 
(.0017  .01)  (.0029  .04) ¼ .00033. (Note that this rate is
higher than the frequency among healthy control subjects). The
penetrance values are expressed as percent in the text and
tables.
Because some of the CNVs are extremely rare or even absent
in control subjects, we provide the 95% conﬁdence intervals
(CI) of the penetrance values, which can be wide in such
instances. These were estimated by ﬁrst producing binomial CIs
for the frequencies of CNVs in each population, using the
Wilson score interval (19). Upper and lower 95% bounds for
penetrance were estimated from the upper bounds of CNV
frequencies in patients and the lower bounds of the frequen-
cies in the general population (and vice versa for the lower
bounds). The details for each CNV are presented in the Table S4
of Supplement 1.
Estimating the selection coefﬁcients acting against CNVs was
performed with the method we presented previously (14).
Brieﬂy, this equates to the proportion of the observed de novo
CNVs in a population, out of the total number of CNVs observed
in that population (de novo  inherited). We updated our
previous estimates with new data published since and added
loci that were not part of our previous paper (Table S3 in
Supplement 1).Results
The rates of CNVs among subjects affected with SCZ, those
with DD/ASD/CM, and healthy control subjects are presented in
Figure 1 and the full details in Tables S2 and S4 in Supplement 1.
Almost all CNVs have higher rates in the DD/ASD/CM group
compared with SCZ. The instances in which these differences are
signiﬁcantly higher are indicated with asterisks in Figure 1. The
only occasions in which the rates in SCZ patients are higher are
for the 16p11.2 duplication, 3q29 deletion, 16p13.11 duplication,
and the “smaller 15q13.3 (CHRNA7)” duplication, but these
differences are small and not signiﬁcant. In contrast, there are
numerous occasions of CNVs that are much more frequent in DD/
ASD/CM, some differences are highly signiﬁcant, and some CNVs
have not yet been reported in SCZ cases.
The differences between the penetrance of CNVs for the
different disorders are even more striking (Figure 2 and Table S4
in Supplement 1). For CNVs that are never observed in control
subjects, the joint penetrance reaches 100%, but we should point
out that for some of the cases with 100% penetrance, the 95% CIs
are large (Supplement 1). It is known that the penetrance for
some syndromic disorders, like Prader-Willi syndrome/Angelman
syndrome (PWS/AS), is indeed nearly complete (i.e., they are not
found in healthy control subjects), nor are they found in SCZ
subjects. Furthermore, their 95% CIs are tighter.
Psychiatrists are likely to be more interested in the penetrance
of SCZ-associated CNVs. Therefore, we present them separately in
Figure 3 and Table 1. All of them have much higher penetrance
for DD/ASD/CM than for SCZ. The frequency of a CNV (and
therefore its penetrance) separately for ASD, for DD, or for speciﬁc
CM will of course differ for each CNV and is not known in each
Figure 1. Frequencies of copy number variants among individuals with schizophrenia (gray) and the combined group of developmental delay, autism
spectrum disorders, and various congenital malformations (black). Deletions are on the left and duplications on the right of the ﬁgure. VCFS, velo-cardio-
facial syndrome. *p  .05; **p  .001; ***p  .00001.
G. Kirov et al. BIOL PSYCHIATRY 2014;75:378–385 381case. This remains to be established in the future and is not a
topic of this article. The total penetrance for any disorder
(including SCZ) for this set of CNVs ranges from 10.6% for the
16p13.11 duplication to 100% for the VCFS deletion, (mean of
41%). The 95% CIs for this set of CNVs are much tighter because
they have been tested in larger numbers of control subjects, and
therefore the penetrance estimates are more reliable.
The selection coefﬁcients for the CNVs and the sources we used to
derive them are presented in Table S3 of Supplement 1. Our data are
insufﬁcient for a conﬁdent estimate of the selection coefﬁcients for
many of the CNVs, so for our comparison with the penetrance data,
we use only CNVs for which at least ﬁve observations on their
inheritance status are available from systematically conducted studies.
The results are shown in Figure 4A. The strength of selection against
CNVs correlated strongly with their overall penetrance for any
disorder: Pearson correlation r ¼ .51, p ¼ .001. There are some
obvious exceptions to the rule, with CNVs not seen in control subjects(and therefore have a penetrance of 100%) having only modest
selection coefﬁcients. As a rule, these exceptions are based on smaller
number of observations and have wide 95% CIs, up to 0% to 100%
(Table S4 in Supplement 1). We therefore excluded CNVs with a
penetrance of 100% that have lower bounds of the 95% CI below
10% (an arbitrarily chosen cutoff). Most of the outliers disappeared
(Figure 4B), and the correlation increased to r ¼ .83, p  10–6.Discussion
The role of CNVs in the pathogenesis of SCZ and devel-
opmental disorders is well established (6–8,20). The penetrance of
some of these CNVs has been estimated before but separately for
these disorders (9,10). The estimates for SCZ (9) had produced
modest rates of 2% to 7.4% for seven SCZ-associated CNVs
(excluding the 22q11.2 deletion). The estimates for DD/ASD/CMwww.sobp.org/journal
Figure 2. Penetrance of copy number variants. The layout is the same as for Figure 1. VCFS, velo-cardio-facial syndrome.
382 BIOL PSYCHIATRY 2014;75:378–385 G. Kirov et al.(10) for a small subset of CNVs produced higher estimates of 10%
to 62%, but only three loci overlapped between these studies. Our
estimates for the penetrance and the 95% CIs for the two
phenotypes are reassuringly similar to these previous reports:
Pearson correlation of .82 for SCZ and .68 for DD/ASD/CM (Table
S5 in Supplement 1). The only exception is the 22q11.2 deletion in
which the penetrance for SCZ was estimated at 55% by Vassos
et al. (10) and 12% by us. However, these authors pointed out that
the credible intervals for this CNV were broad because no CNV was
observed in a control, and they relied on simulations. Accurate data
on DD/ASD/CM were not available at that time, and these greatly
help the estimates. Because our results are based on larger sample
sizes for every CNV tested, they are likely to be more accurate. Even
for CNVs that are found at similar rates in the two phenotypes, the
penetrance is several times higher for the DD/ASD/CM group. This
is because the frequency of the group of DD/ASD/CM
is approximately 4 times higher in the general population,
indicating that even in those cases in which the rate of a CNV is
similar, still about 4 times more CNV carriers will develop a DD/www.sobp.org/journalASD/CM phenotype instead of SCZ. Even large errors in our
assumptions for the population frequencies of SCZ and the group
of DD/ASD/CM cannot change the conclusion that the penetrance
is higher for the group of DD/ASD/CM.
Different arrays have been used in the studies, and therefore we
need ensure that this did not create the differences we observe. The
CNV frequencies in SCZ cases and controls are based on similar or
identical arrays. Thus, the ISC and MGS samples have both cases and
controls of similar numbers, and they have been genotyped on
the same (Affymetrix, Santa Clara, California) arrays, whereas the
Clozapine UK/Cardiff University Cognition in Schizophrenia and the
corresponding controls from the smoking, melanoma, Kooperative
Gesundheitsforschung in der Region Augsburg (KORA), and WTCCC2
studies were analyzed with only the 520,766 overlapping probes on
Illumina arrays (Table S1 in Supplement). The data on the DD/ASD/
CM samples is based on different, custom-made, whole-genome,
bacterial artiﬁcial chromosome versions or oligonucleotide-based
arrays (7,10). These arrays have fewer probes than those used for
the SCZ cases and controls and, as a consequence, could have a
Figure 3. Penetrance of schizophrenia-associated copy number variants
for schizophrenia (gray) and the combined group of developmental delay,
autism spectrum disorders, and various congenital malformations (black).
AS/PWS, Angelman/Prader-Willi syndrome; del, deletion; dup, duplication;
VCFS, velo-cardio-facial syndrome; WBS, Williams-Beuren syndrome.
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custom-made arrays, the differences we ﬁnd would be even higher.
In any case, most CNVs tested are large and should be detected on
any of these arrays. We made sure that even the limited number of
small CNVs analyzed in the DD/ASD/CM samples (those for single
genes) were covered with sufﬁcient number of probes from the list
of probes common on all Illumina arrays used in our study and
would thus be detected on these arrays as well. As presented in
Table S2 of Supplement 1, only a small number of CNVs are covered
with fewer than 15 probes on the Illumina arrays, and these CNVs are
not relevant for our conclusions. Even more reassuringly, the most
striking differences between DD/ASD/CM and SCZ are found for very
large CNVs, which should be detected on any arrays (e.g., the
deletions at the AS/PWS and Williams-Beuren syndrome regions; at
1p36, 16p11.2, 17q21.31; and the duplications at 22q11.2 and 22q13
that show differences at p  10–5) are covered with at least 80
probes (Table S2 in Supplement 1).
The rather modest penetrance values produced for SCZ in the
previous literature have been taken as evidence that these CNVs
have low penetrance and are neither sufﬁcient, nor necessary forFigure 4. Correlation between the overall penetrance and selection coefﬁcien
conﬁdence intervals, see text.the development of SCZ. The current data highlights the point that
most of these CNVs are in fact highly pathogenic, but the
phenotype that they produce is more likely to be another
developmental disorder, such as DD or ASD. Thus the average
penetrance for the SCZ-associated CNVs from Table 1 is 41% for
developing any of the disorders discussed here, ranging from 10.6%
(95% CI ¼ 7–17%) for the 16p13.11 duplication, to 100% (95% CI ¼
60–100%) for the VCFS deletion. These are very substantial increases
in risk for developing a serious disorder, such as SCZ, DD, ASD, and
certain CM. As not all controls have been screened for neuro-
psychiatric phenotypes, it is possible that some carriers of CNVs
from the control populations also have some subtle phenotypes,
which would result in even higher penetrance estimates, so our
ﬁgures might even be an underestimate. The high pathogenicity of
these CNVs is supported by the estimates of high selection pressure
that operates against them, and the two show a striking correlation
(Figure 4B), despite being derived at with different methods (one
based of frequencies, the other on de novo ratios). The increase in
risk to develop one of these disorders appears to result in a similar
increase in the selection pressure against their carriers. This
indicates that the selection coefﬁcient (the de novo ratio) is a good
predictor for the penetrance of a CNV, and vice versa. For many of
the 70 CNVs discussed here, the number of observations used for
the de novo ratios or for the frequencies are too small, leading to
unreliable estimates for the penetrance and selection coefﬁcients.
These estimates should be reﬁned in future studies.
Additional disorders that have not been speciﬁcally discussed here
but are also reported in carriers of these CNVs include, among others,
epilepsy (4) and attention-deﬁcit/hyperactivity disorder (21). It is not
the scope of this article to discuss the exact range of phenotypic
presentations of each of these CNVs. They are variable and in some
cases not yet reliably established. What is more important is the fact
that the presence of one of these CNVs has consequences for genetic
counselling and diagnosis. Because the penetrance for a severe
neurodevelopmental disorder among children of carriers is greater
than 10%, this raises important questions in a genetic counselling
setting because the offspring of carriers who inherit one of these
CNVs (Table 1) will have a risk for developing one of these disorders
of between 10% and 100% (ignoring any additional risk from other
inherited genetic variants). In most instances, this will be higher than
the 12.8% to 15% risk among children of SCZ patients in general (22).
The presence in a patient of most other CNVs from the list proposed
by Girirajan et al. (7) should also be considered important for thets of copy number variants. (A) All data. (B) Excluding data with wide 95%
www.sobp.org/journal
384 BIOL PSYCHIATRY 2014;75:378–385 G. Kirov et al.diagnosis and management of the person. There are some notable
exceptions to the rule, for example, the “smaller 15q13.3” duplication
is present at equal rates in cases and controls and is not considered
pathogenic by us or by Girirajan et al. (7).
A question that arises is what determines the neurodevelop-
mental trajectory toward SCZ or severe developmental delay/
intellectual disability for carriers of the same CNV. One possible
explanation is the presence of a second large and rare CNV
among carriers of pathogenic CNVs (7). We tested this hypothesis
on the subset of SCZ-associated CNVs because these are the CNVs
for which we have sufﬁcient numbers to produce valid results
(many of the most pathogenic CNV loci analyzed by Girirajan et al.
(7) are not hit by CNVs in SCZ patients). We used the same criteria
to deﬁne a “second hit,” as suggested by Girirajan et al. (7): large
(500 kb) and rare CNVs (.1% frequency in control popula-
tions), or a known pathogenic CNV (from the list of 70 CNV, Table
S2 in Supplement 1), even if 500 kb. The rate of such “second
hits” (Table S6 in Supplement 1) was however, nearly identical for
patients with SCZ and those with DD/ASD/CM, at 10% versus
9.3% (p ¼ .74), indicating that the presence of a second hit CNV is
not the factor that usually determines the phenotype of carriers.
The current study also strengthens the now-established evi-
dence of a genetic overlap among DD, ASD, and SCZ, at least for a
subset of CNVs. It appears that some CNVs are so highly pathogenic
and penetrant that they cause earlier-onset disorders (DD/ASD) and
not SCZ. Indeed, severe DD or ASD, particularly in the presence of
a clear chromosomal syndrome, is likely to preclude a clinical
diagnosis of SCZ. These are for example the Angelman/Prader-Willi
syndrome, Williams-Beuren syndrome, and the 1q36 deletion
syndrome. Other CNVs can present with DD/ASD or lead later in
life to SCZ (Table 1). They still have a much higher penetrance for
an early-onset disorder (Figure 3). No CNV from this list speciﬁcally
increases risk to develop SCZ rather than DD/ASD/CM.
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